Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, BHVN is expected to report 2Q20 loss of $ 2.61 per share from revenue of $ 7.65 million.
For the full year, analysts anticipate top line of $ 52.52 million, while looking forward to loss of $ 10.19 per share bottom line.
Previous Quarter Performance
Biohaven Pharmaceutical Holding Company Ltd. communicated loss for the first quarter of $ 2.39 per share, from the revenue of $ 1.15 million. The quarterly revenues compared with the same quarter last year. According to street consensus, revenue of was expected for the first quarter The bottom line results street analysts by $ 0.26 or , at the same time, top line results analysts by $ 2.09 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of BHVN was $ 67.65, representing a 154.71 % increase from the 52 week low of $ 26.56 and a 14.1 % decrease over the 52 week high of $ 78.75.
The company has a market capital of $ 3.96 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BHVN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 15th July 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 60.00 target price.
Conference Call
Biohaven Pharmaceutical Holding Company Ltd. will be hosting a conference call at 8:00 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biohavenpharma.com
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation.
